

September 28, 2016



# Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility

EDMONTON, ALBERTA -- (Marketwired) -- 09/28/16 -- [Ceapro Inc. \(TSX VENTURE:CZO\)](#) ("**Ceapro**" or the "**Company**"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the grand opening of its new 30,000-square-foot bioprocessing extraction/manufacturing facility in Edmonton, Alberta, Canada.

Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, stated, "The grand opening of our new bio-processing extraction facility is a notable step forward in our corporate development. We are thrilled to celebrate with dignitaries, corporate partners and members of the press and launch the production of our first commercial batch of oat extracts at our new facility."

In conjunction with the grand opening, today the Company will be hosting a press conference event with Premier Rachel Notley as well as other dignitaries and corporate representatives at 10:30 a.m. MDT.

"We are incredibly thankful for the support and partnerships we have received in the process of building Ceapro's new facility, which will enable the development of new bio-products and technologies. We are grateful for Alberta Innovates Bio Solutions, Agrivalve Processing Business Incubator, National Research Council, Agriculture Financial Services Corp, Agriculture and Agri-Food Canada and our partner, Symrise AG, for their continued support and funding contributions along with a number of other partners, contributors and supporting organizations," added Mr. Gagnon.

"As we transfer our manufacturing to our new facility, we will seamlessly and without interruption continue to develop our pipeline and execute our projects rigorously toward market expansion into the profitable nutraceutical and pharmaceutical sectors," concluded Mr. Gagnon.

In addition to current extraction fractionation process technologies, Ceapro's new bio-processing GMP facility includes an expanded production area specifically designed to house a commercial and demonstration scale PGX skid and an ethanol recycling system which will make Ceapro a "greener" company. In addition to utilizing PGX for production of Ceapro's cosmeceutical value-driver beta glucan, the Company has in-licensed its proprietary PGX enabling technology for worldwide use in all industries and all applications and is developing PGX at the commercial scale level.

Steve Price, President and Chief Operating Officer of Alberta Innovates Bio Solutions, commented, "Ceapro's bioprocessing facility is the most commercialized project to which we have contributed. We were particularly impressed with the potential of the Company's novel

[Pressurized Gas eXpanded \(PGX\) technology](#), which may provide the foundation of an innovation technology hub in Alberta. PGX is capable of processing a range of bio-based feedstocks, and so it also has the potential to generate many new types of bioproducts. We are extremely pleased to be part of this great 'made in Alberta' success story."

***About Ceapro Inc.***

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at [www.ceapro.com](http://www.ceapro.com).

***Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

Source: Ceapro Inc.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas

Jenene Thomas Communications, LLC

Investor Relations and Corporate Communications Advisor

(US): 908-938-1475

[jenene@jenenethomascommunications.com](mailto:jenene@jenenethomascommunications.com)

Source: Ceapro Inc.